Azithromycin and Coronavirus (COVID-19)

coronavirus COVID-19

In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named “2019 novel coronavirus (2019-nCoV)” by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed.

Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University.

This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Such pathogens can cause severe and often deadly infections and pose a dire threat to people with weak or not fully developed immune systems, such as cancer patients, newborns, the elderly, and people undergoing surgery. Respiratory tract infection was diagnosed, and empirical antibiotics were started. Within two days, she developed bilateral pleural effusions, diffuse consolidations, and ground glass opacities involving all lung fields.

China on March 8 reported its lowest number of new coronavirus infections since January, with nearly all the 44 new cases in the outbreak epicenter Wuhan. Although results were independent of study duration, it is possible that the protective effect of azithromycin could have been stronger had all participants been followed for 78 weeks. Acute care emergency department visits and hospitalizations for respiratory illnesses were infrequent, both in the year preceding the study and during the study, potentially reflecting enrollment of a population at low risk for hospitalization. There were 29 heart-related deaths among those who took Zithromax during five days of treatment. Their risk of death while taking the drug was more than double that of patients on another antibiotic, amoxicillin, or those who took none.

The cost of an antibiotic used to treat several bacterial infections, azithromycin, has also risen by approximately 70 per cent, as mentioned by Pankaj R Patel, chairman of Zydus Cadila, as mentioned in a report in Bloomberg. Some countries, including the United States, have put restrictions on Chinese travelers entering and advised their citizens against travel to China.

Was this article helpful?